AbstractCyclophosphamide is a widely-used alkylating agent with cytotoxic effects, as well as an immunosuppressive agent. In the past, life-threatening hyponatremia had been reported as a rare complication induced by both high-dose and low-dose cyclophosphamide. We presented a breast cancer patient who had generalized seizure after the second cycle of adjuvant cyclophosphamide plus epirubicin, as her serum sodium concentration dropped from 134 mmol/L to 115 mmol/L within one day. Complete recovery was achieved after her hyponatremia was corrected and we further successfully completed two additional cycles of cyclophosphamide. Clinicians should always keep in mind this rare but severe adverse effect of cyclophosphamide, in order to make the ...
Gemcitabine (GEM) is currently a standard chemotherapeutic agent for metastatic urothelial carcinoma...
Pertuzumab is a molecular-targeted drug that binds to the extracellular domain of human epidermal gr...
Background: Thalidomide was introduced in the 1950s as a nontoxic sedative, but was removed from the...
AbstractCancer-related hypercalcemia is a relative common complication from breast cancer with bone ...
AbstractAlthough current treatment can improve the complete remission rate of T-cell acute lymphobla...
AbstractOlfactory neuroblastoma is a rare intranasal tumor, and the standard treatment for this dise...
Background Muscle wasting, anorexia, and metabolic dysregulation are common side-effects of cytot...
This is a case of 32 years old nulliparous female who was diagnosed in November 2004 as a case of ca...
Antibiotics (AB) remain the main etiotropic drugs in the treatment of patients with community-acquir...
Breast cancer (BC) is the second most common cancer that causes higher mortality rates worldwide. It...
The aim of our study was to evaluate efficiency of the use of ethylmethyl-dyroxypiridine sukcinate i...
Diacerein is a new generation of symptomatic slow-acting agent for the treatment of osteoarthritis, ...
Adequate haemostasis after trauma and during surgical operation is a big challenge in modern medicin...
Introduction/Objective: To report a case of ocular toxicity related to two chemotherapeutic regimens...
[[abstract]] 本研究為橫斷性調查(cross-sectional study),利用問卷配合面對面訪談收集資料,研究期間為2007年4月1日至7月31日,共訪談中部某醫學中心208位正接...
Gemcitabine (GEM) is currently a standard chemotherapeutic agent for metastatic urothelial carcinoma...
Pertuzumab is a molecular-targeted drug that binds to the extracellular domain of human epidermal gr...
Background: Thalidomide was introduced in the 1950s as a nontoxic sedative, but was removed from the...
AbstractCancer-related hypercalcemia is a relative common complication from breast cancer with bone ...
AbstractAlthough current treatment can improve the complete remission rate of T-cell acute lymphobla...
AbstractOlfactory neuroblastoma is a rare intranasal tumor, and the standard treatment for this dise...
Background Muscle wasting, anorexia, and metabolic dysregulation are common side-effects of cytot...
This is a case of 32 years old nulliparous female who was diagnosed in November 2004 as a case of ca...
Antibiotics (AB) remain the main etiotropic drugs in the treatment of patients with community-acquir...
Breast cancer (BC) is the second most common cancer that causes higher mortality rates worldwide. It...
The aim of our study was to evaluate efficiency of the use of ethylmethyl-dyroxypiridine sukcinate i...
Diacerein is a new generation of symptomatic slow-acting agent for the treatment of osteoarthritis, ...
Adequate haemostasis after trauma and during surgical operation is a big challenge in modern medicin...
Introduction/Objective: To report a case of ocular toxicity related to two chemotherapeutic regimens...
[[abstract]] 本研究為橫斷性調查(cross-sectional study),利用問卷配合面對面訪談收集資料,研究期間為2007年4月1日至7月31日,共訪談中部某醫學中心208位正接...
Gemcitabine (GEM) is currently a standard chemotherapeutic agent for metastatic urothelial carcinoma...
Pertuzumab is a molecular-targeted drug that binds to the extracellular domain of human epidermal gr...
Background: Thalidomide was introduced in the 1950s as a nontoxic sedative, but was removed from the...